Fundraising FoxDomain Partners — 2015 Investments
1 investments dated 2015 · listed companies and verified rows first · show all
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Board seatJames C. Blair· per SEC Form D · $76.3M raise · filed Apr 2015
Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesViking GlobalDomain AssociatesPolaris Partners+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.